Call for entries to ASTRO's annual Survivor Circle Award

Posted on by

Contact Information

Available for logged-in reporters only

Newswise April 4, 2014 The American Society for Radiation Oncology (ASTRO) seeks to recognize an individual cancer survivor in the San Francisco Bay area who has dedicated his or her time and energy to helping their local community. The winner of ASTROs 2014 Survivor Circle Award will receive $1,000 and will be honored at a ceremony at San Franciscos Moscone Center on Tuesday, September 16, 2014. The Survivor Circle Award will be presented at ASTROs 56th Annual Scientific Meeting, an international medical meeting hosting more than 11,000 radiation oncology physicians and professionals, to be held September 14-17, 2014, at San Franciscos Moscone Center.

Cancer survivors are the best advocates for patients, and they provide us with valuable information as we focus our techniques and technologies to optimize treatment outcomes, said Bruce D. Minsky, MD, president-elect of ASTRO. The Survivor Circle Award will honor a Bay area resident who is providing exemplary volunteerism and leadership in their community.

Any cancer survivor residing within the metropolitan San Francisco Bay area who received radiation therapy as part of their treatment and who is giving back to their community through volunteer efforts is eligible to enter. The winner may keep the cash prize of $1,000 or may donate the award to a support organization or charity of his or her choice. The application is online at http://www.rtanswers.org/scaward/. Applications must be postmarked by June 1, 2014.

Since 2003, ASTRO has recognized cancer survivors in the city where its Annual Scientific Meeting is held. In addition to recognizing a local individual each year, ASTRO provides grants to patient advocacy groups that help patients and their families cope with a cancer diagnosis. These organizations are featured in the Survivor Circle during ASTROs Annual Meeting.

Cancer survivors are a vital resource as we push for increased patient survival and improved outcomes, said Laura I. Thevenot, ASTRO CEO. These awards honor the leadership, dedication and strength of the many patient advocates and patient support organizations nationwide.

Applications for the 2014 Survivor Circle Award must be postmarked by Sunday, June 1, 2014. The application is available at: http://www.rtanswers.org/survivorship/survivorcircle/SurvivorCircleAward.

For more information on ASTROs 56th Annual Meeting, please visit http://www.astro.org/AnnualMeeting.

For more information on radiation therapy, please visit http://www.rtanswers.org.

See the article here:

Call for entries to ASTRO's annual Survivor Circle Award

Dose-Escalated Hypofractionated IMRT for Localized Prostate Cancer Has Similar Side Effects When Compared to …

Posted on by

Contact Information

Available for logged-in reporters only

Newswise Fairfax, Va., April 3, 2014Dose-escalated intensity modulated radiation therapy (IMRT) with use of a moderate hypofractionation regimen (72 Gy in 2.4 Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a study published in the April 1, 2014 edition of the International Journal of Radiation Oncology Biology Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

Previous randomized clinical trials have shown that dose-escalated radiation therapy improves prostate cancer control compared to lower-dose conventional radiation therapy. Conventional fractionation of dose-escalated radiation therapy (1.8 or 2 Gy fractions) can take up to nine weeks to complete, while hypofractionated radiation therapy can deliver a higher biologically effective dose over a shorter period of time (six weeks) and has the potential to increase prostate cancer control without increasing toxicity. However, there are limited data on the late toxicity of moderate hypofractionated regimens for prostate cancer. This randomized trial from the University of Texas MD Anderson Cancer Center compares the late toxicity outcomes of men with localized prostate cancer treated with either conventionally fractionated IMRT (CIMRT) or dose-escalated hypofractionated IMRT (HIMRT).

Men with organ-confined prostate cancer were enrolled in this institutional review board-approved trial from January 2001 to January 2010 and were randomized to receive either CIMRT (75.6 Gy in 1.8 Gy fractions over eight-and-a-half weeks) or HIMRT (72 Gy in 2.4 Gy fractions over six weeks). Eligible patients had biopsy-proven prostate adenocarcinoma; good performance status; stage T1b-T3b disease; a prostate-specific antigen (PSA) 20 ng/ml; a Gleason score <10; and no clinical, radiographic or pathologic evidence of nodal or bone metastasis. Patients with stage cT3c or cT4 disease, a history of prior pelvic radiation therapy, or who received more than four months of hormone ablation therapy with prior or planned radical prostate surgery and with concurrent active malignancy other than nonmetastatic skin cancer or early-stage chronic lymphocytic leukemia were not eligible for the trial. The median age of the patient cohort was 68. Of the 203 patients analyzed in the study, 72 percent had stage T1 disease (146) and 89 percent had a PSA <10 ng/ml (181). Thirty-four percent (70) had Gleason 6 disease, 65 percent (131) had Gleason 7 disease and 1 percent (2) had Gleason 8 disease. Patients were classified into low-risk (28 percent = 57), intermediate risk (71 percent = 144) and high-risk (1 percent = 2) disease using current National Comprehensive Cancer Network risk-group definitions.

All patients were treated with static-field IMRT. One hundred and one (101) men received CIMRT and 102 men received HIMRT. Physician-reported toxicity was evaluated for all patients during treatment and at each follow-up visit. After completion of radiation therapy, follow-up was conducted at least every six months for the first two years post-treatment, and annually thereafter. Median follow-up was six years.

Late gastrointestinal (GI) and genitourinary (GU) toxicity were analyzed in this study, starting 90 days post-treatment, using modified Radiation Therapy Oncology Group toxicity grading. In the CIMRT arm, 17 percent (17) experienced grade 1 GI toxicity, 4 percent (4) experienced grade 2 GI toxicity and 1 percent (1) experienced grade 3 GI toxicity. In the HIMRT arm, 26 percent (27) experienced grade 1 GI toxicity, 9 percent (9) experienced grade 2 GI toxicity and 2 percent (2) experienced grade 3 GI toxicity. There was a numeric increase in the absolute frequency of late GI toxicity for men treated with HIMRT, but the difference was not statistically significant. The five-year actuarial grade 2 or 3 late GI toxicity was 5.1 percent (95 percent Confidence Interval (CI)) for patients treated with CIMRT and 10 percent for patients treated with HIMRT. The increase in late GI toxicity for men receiving HIMRT was the result of moderate and high radiation dose to a larger proportion of the rectum, which suggests that more stringent dose constraints for the rectum may result in lower late GI toxicity for those patients.

Additionally, there was not a statistically significant difference in the absolute frequency of late GU toxicity in men treated with CIMRT or HIMRT. In the CIMRT arm, 15 percent (15) experienced grade 1 GU toxicity, 14 percent (14) experienced grade 2 GU toxicity and 1 percent (1) experienced grade 3 GU toxicity. In the HIMRT arm, 10 percent (10) experienced grade 1 GU toxicity and 15 percent (15) experienced grade 2 GU toxicity; no patients reported grade 3 GU toxicity. The five-year actuarial grade 2 or 3 late GU toxicity was 16.5 percent (95 percent CI) for patients treated with CIMRT and 15.8 percent for patients treated with HIMRT.

These results demonstrate that the length of radiation treatment for prostate cancer can be safely decreased to six weeks (from eight-and-a-half weeks) by delivering larger daily doses of radiation without increasing the urinary and bowel effects, said Karen E. Hoffman, MD, a co-author of the study and assistant professor in the Division of Radiation Oncology at the University of Texas MD Anderson Cancer Center in Houston. Decreasing the length of treatment decreases the cost and is more convenient for patients.

For a copy of the manuscript of the study, contact Brittany Ashcroft at 703-839-7336, press@astro.org. For more information about the Red Journal, visit http://www.redjournal.org.

Go here to read the rest:

Dose-Escalated Hypofractionated IMRT for Localized Prostate Cancer Has Similar Side Effects When Compared to ...

Dose-escalated hypofractionated IMRT, conventional IMRT for prostate cancer have like side effects

Posted on by

PUBLIC RELEASE DATE:

3-Apr-2014

Contact: Brittany Ashcroft press@astro.org 703-839-7336 American Society for Radiation Oncology

Fairfax, Va., April 3, 2014Dose-escalated intensity modulated radiation therapy (IMRT) with use of a moderate hypofractionation regimen (72 Gy in 2.4 Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a study published in the April 1, 2014 edition of the International Journal of Radiation Oncology Biology Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

Previous randomized clinical trials have shown that dose-escalated radiation therapy improves prostate cancer control compared to lower-dose conventional radiation therapy. Conventional fractionation of dose-escalated radiation therapy (1.8 or 2 Gy fractions) can take up to nine weeks to complete, while hypofractionated radiation therapy can deliver a higher biologically effective dose over a shorter period of time (six weeks) and has the potential to increase prostate cancer control without increasing toxicity. However, there are limited data on the late toxicity of moderate hypofractionated regimens for prostate cancer. This randomized trial from the University of Texas MD Anderson Cancer Center compares the late toxicity outcomes of men with localized prostate cancer treated with either conventionally fractionated IMRT (CIMRT) or dose-escalated hypofractionated IMRT (HIMRT).

Men with organ-confined prostate cancer were enrolled in this institutional review board-approved trial from January 2001 to January 2010 and were randomized to receive either CIMRT (75.6 Gy in 1.8 Gy fractions over eight-and-a-half weeks) or HIMRT (72 Gy in 2.4 Gy fractions over six weeks). Eligible patients had biopsy-proven prostate adenocarcinoma; good performance status; stage T1b-T3b disease; a prostate-specific antigen (PSA) 20 ng/ml; a Gleason score <10; and no clinical, radiographic or pathologic evidence of nodal or bone metastasis. Patients with stage cT3c or cT4 disease, a history of prior pelvic radiation therapy, or who received more than four months of hormone ablation therapy with prior or planned radical prostate surgery and with concurrent active malignancy other than nonmetastatic skin cancer or early-stage chronic lymphocytic leukemia were not eligible for the trial. The median age of the patient cohort was 68. Of the 203 patients analyzed in the study, 72 percent had stage T1 disease (146) and 89 percent had a PSA <10 ng/ml (181). Thirty-four percent (70) had Gleason 6 disease, 65 percent (131) had Gleason 7 disease and 1 percent (2) had Gleason 8 disease. Patients were classified into low-risk (28 percent = 57), intermediate risk (71 percent = 144) and high-risk (1 percent = 2) disease using current National Comprehensive Cancer Network risk-group definitions.

All patients were treated with static-field IMRT. One hundred and one (101) men received CIMRT and 102 men received HIMRT. Physician-reported toxicity was evaluated for all patients during treatment and at each follow-up visit. After completion of radiation therapy, follow-up was conducted at least every six months for the first two years post-treatment, and annually thereafter. Median follow-up was six years.

Late gastrointestinal (GI) and genitourinary (GU) toxicity were analyzed in this study, starting 90 days post-treatment, using modified Radiation Therapy Oncology Group toxicity grading. In the CIMRT arm, 17 percent (17) experienced grade 1 GI toxicity, 4 percent (4) experienced grade 2 GI toxicity and 1 percent (1) experienced grade 3 GI toxicity. In the HIMRT arm, 26 percent (27) experienced grade 1 GI toxicity, 9 percent (9) experienced grade 2 GI toxicity and 2 percent (2) experienced grade 3 GI toxicity. There was a numeric increase in the absolute frequency of late GI toxicity for men treated with HIMRT, but the difference was not statistically significant. The five-year actuarial grade 2 or 3 late GI toxicity was 5.1 percent (95 percent Confidence Interval (CI)) for patients treated with CIMRT and 10 percent for patients treated with HIMRT. The increase in late GI toxicity for men receiving HIMRT was the result of moderate and high radiation dose to a larger proportion of the rectum, which suggests that more stringent dose constraints for the rectum may result in lower late GI toxicity for those patients.

Additionally, there was not a statistically significant difference in the absolute frequency of late GU toxicity in men treated with CIMRT or HIMRT. In the CIMRT arm, 15 percent (15) experienced grade 1 GU toxicity, 14 percent (14) experienced grade 2 GU toxicity and 1 percent (1) experienced grade 3 GU toxicity. In the HIMRT arm, 10 percent (10) experienced grade 1 GU toxicity and 15 percent (15) experienced grade 2 GU toxicity; no patients reported grade 3 GU toxicity. The five-year actuarial grade 2 or 3 late GU toxicity was 16.5 percent (95 percent CI) for patients treated with CIMRT and 15.8 percent for patients treated with HIMRT.

"These results demonstrate that the length of radiation treatment for prostate cancer can be safely decreased to six weeks (from eight-and-a-half weeks) by delivering larger daily doses of radiation without increasing the urinary and bowel effects," said Karen E. Hoffman, MD, a co-author of the study and assistant professor in the Division of Radiation Oncology at the University of Texas MD Anderson Cancer Center in Houston. "Decreasing the length of treatment decreases the cost and is more convenient for patients."

Read the original here:

Dose-escalated hypofractionated IMRT, conventional IMRT for prostate cancer have like side effects

Artificial Intelligence Is The Next Frontier For Social Networks

Posted on by

BI Intelligence

Now, though, Facebook, Twitter, LinkedIn, and others are beginning to use artificial intelligence techniques to build out their "deep learning" capacities. They're starting to process all the activity occurring over their networks, from conversations, to photo facial recognition, to gaming activity.

In arecent reportfromBI Intelligence, we show how advancesin cutting-edge artificial intelligence research, which program machines to perform high-level thought and abstractions,are helping social networks and their advertisers glean insights from this vast ocean of unstructured consumer data. Thanks to deep learning, social media has the potential to become far more personalized. New marketing fields are quickly emerging, too:audience clustering, predictive marketing, and sophisticated brand sentiment analysis.

Access The Full Report By Signing Up For A Free Trial Today >>

Here are some of the major acquisitions and hires from the AI field that occurred in recent months:

In full, the report:

For full access to all BI Intelligence's charts and data on social media, mobile, video, e-commerce, and payments, sign up for a free trial subscription.

More here:

Artificial Intelligence Is The Next Frontier For Social Networks

Johnny Depp says being famous is like being a 'fugitive'

Posted on by

NEW YORK, April 4 (UPI) -- Johnny Depp still hasn't gotten used to fame, and says being a celebrity is akin to "living like a fugitive."

The notoriously private star appeared in an interview Friday on Today to discuss his new film, Transcendence. The 50-year-old actor also confirmed his engagement to 27-year-old model and actress Amber Heard, after rumors of the pair's commitment were left unanswered for months.

"Everything has to be some sort of a strategy," Depp says of life in the spotlight. "[It's] a little bit like liking like a fugitive... To get you into the hotel, to get you out of the hotel, to get you into the restaurant, to get you out of the restaurant."

The actor takes care to acknowledge his fans, and says he is "honored" by their support and loyalty. He affirms he will always be there for them, "because those people that buy the tickets are the people that I consider my boss."

Depp portrays artificial intelligence researcher Dr. Will Caster in his new movie, Transcendence. The film marks longtime cinematographer Wally Pfister's directorial debut, and is produced by Christopher Nolan and Emma Thomas.

Caster is a researcher whose mind is uploaded to his project's computer after he suffers an injury. The machine possesses sentience and collective intelligence abilities, and extremists opposed to technological advancement attempt to stop Caster and the computer.

The actor admits that his role in the sci-fi thriller had little effect on his own technological skills.

"I'm a complete and utter oaf," Depp says of his attempts to text message. "A grown man...attempting to send an important message with these thumbs? You know, it's truly given meaning to the expression, 'I'm all thumbs.'"

Transcendence debuts in theaters on April 17.

Read the original:

Johnny Depp says being famous is like being a 'fugitive'

Breakthroughs in Nanomedicine-A World Economic Forum Discussion-Ideas @Davos-WIRED – Video

Posted on by


Breakthroughs in Nanomedicine-A World Economic Forum Discussion-Ideas @Davos-WIRED
In this World Economic Forum discussion, the University of Oxford #39;s Dr. Sonia Trigueros challenges the way we think about antibiotics and offers an alternati...

By: WIRED

View original post here:
Breakthroughs in Nanomedicine-A World Economic Forum Discussion-Ideas @Davos-WIRED - Video

Agnostic | What is the Definition of Agnostic …

Posted on by

Origin: Greek gnst(os), variant of gntos not known, incapable of being known (a- a-6 + gnts known, adj. derivative from base of gignskein to know) + -ic, after gnostic; said to have been coined by T.H. Huxley in 1869 Related forms

agnostically, adverb

Synonym Study Agnostic, atheist, infidel, skeptic refer to persons not inclined toward religious belief or a particular form of religious belief. An agnostic is one who believes it impossible to know anything about God or about the creation of the universe and refrains from commitment to any religious doctrine. An atheist is one who denies the existence of a deity or of divine beings. Infidel means an unbeliever, especially a nonbeliever in Islam or Christianity. A skeptic doubts and is critical of all accepted doctrines and creeds.

Word story The word agnostic was coined by the English biologist T.H. Huxley in the late 1860s as a member of the now defunct Metaphysical Society, in response to what he perceived as an abundance there of strongly held beliefs. The original usage of the term was confined to philosophy and religion, and referred to Huxley's assertion that anything beyond the material world, including the existence and nature of God, was unknowable. Today the word can be seen applied to questions of politics, culture, and science, as when someone claims to be a political agnostic. In a more recent trend, one can be agnostic simply by not taking a stand on something. In 2010, President Obama called himself agnostic on tax cuts until he had seen all available options. At a forum on sustainable energy in 2008, GE CEO Jeff Immelt said he was fuel agnostic fundamentally. In technology, software or hardware can be said to be agnostic as well. Computer code that can run on any operating system is called platform agnostic, and such services as phone and electric may be considered agnostic if not dedicated to a particular carrier, device, or user interface.

Popular references Agnostic Front: A New York punk band, considered at the forefront of the New York hardcore music scene. Founded in 1983, in existence for over 25 years.

It [agnostic] came into my head as suggestively antithetic to the gnostic of Church history who professed to know so much. T. H. Huxley, Agnosticism Collected Essays, Volume V; Science and Christian Tradition: Essays (1894)

In theory he [Prof. Huxley] is a great and even severe Agnostic,who goes about exhorting all men to know how little they know. R. H. Hutton, Spectator (January 29, 1870)

Militant Agnostic: I don't know, and you don't either Bumper sticker, Northern Sun (Accessed 2010)

Melville is a political agnostic in Billy Buddhe doesn't know with finalitynot because he is indifferent, but because he sees too much. Robert Midler, Exiled Royalties: Melville and the Life We Imagine (2006)

The whole point of it is to make sure that all ideas are on the tableSo what I want to do is to be completely agnostic, in terms of solutions. President Barack Obama, Obama Agnostic on Deficit Cuts, Won't Prejudge Tax Increases Bloomberg Businessweek by Rich Miller (Feb. 11, 2010)

Go here to read the rest:
Agnostic | What is the Definition of Agnostic ...

Religious Freedom as a Human Right Featured in World Religion News Featured Contributor Series

Posted on by

San Francisco, CA (PRWEB) April 02, 2014

WorldReligionNews.com continues its featured contributor series with an article from human rights advocate Margaret Rose Becker, which calls on all to sign a petition to protect the freedom of religion in Europe.

According to Becker, the legislation is a move towards religious discrimination and hatred. Some of the entities that signed the petition are the European Interreligious Forum for Religious Freedom (France), Central-European Religious Freedom Institute (Hungary), Church of Scientology National Affairs Office (United States) and Soteria International (Denmark).

Read the article here.

WorldReligionNews.com has established its "Featured Contributor" program to offer both writers officially affiliated with all faiths and belief systems, as well as independent writers and authors of note, a public platform from which to publish religion focused articles that will reach not only WRN visitors but also appear via syndication partners on sites like CNN, FOX, New York Daily News and others.

If you are an officially affiliated spokesperson/writer who would like to be considered for a "Featured Contributor" article placement on WRN, contact us here: http://www.worldreligionnews.com/contact-us/.

About WorldReligionNews.com WRN exists to cover the news generated by ALL major world religions, A to Z, from Agnosticism to Wicca and all in between, in ways that will inspire, challenge, enlighten, entertain & engage within a framework wired for a connected and distracted world. http://www.WorldReligionNews.com/.

Read more here:
Religious Freedom as a Human Right Featured in World Religion News Featured Contributor Series

Does This Video Show A Skydiver Nearly Being Hit By A Meteorite?

Posted on by

In the video, you can see a small, dark object go whooshing past parachutist Anders Helstrup around the 29-second mark, followed by a slow-motion replay. It sure as hell looks like a rock falling from above the sky, which would presumably be space, but what do I know? A Professional Rock Guy, a.k.a. a geologist, believes it's a meteorite.

Helstrup's jump occurred in the summer of 2012, according to Norway's state broadcaster NRK. (A legit news source, which matters very much in a story like this one.) He says he didn't notice anything during the jump, but saw the object streak past him upon watching the video.

"When we stopped the film, we could clearly see something that looked like a stone. At first it crossed my mind that it had been packed into a parachute, but it's simply too big for that."

Helstrup shared the video with experts at Oslo's Natural History museum, and it quickly became a sensation among "meteorite enthusiasts." They aided Helstrup in searching the area, which has been narrowed down to 10 square kilometers. But no luckit's damned hard to find a rock, especially when it may not necessarily stand out.

Judging just from the video, geologist Hans Amundsen believes it must be a meteoritespecifically, a small chunk of a larger body that likely broke apart miles above Helstrup.

"It can't be anything else. The shape is typical of meteorites a fresh fracture surface on one side, while the other side is rounded."

But we'll never know. My headline being constructed as a question is not meant to invoke Betteridge's Law, but reflects a genuine agnosticism. Would I love to believe this is the first ever image of a meteorite in "dark flight," after it has decelerated to terminal velocity and no longer carries a bright tail? You bet. It could also be Jimmy fucking Kimmel.

[NRK]

Visit link:
Does This Video Show A Skydiver Nearly Being Hit By A Meteorite?

Umbilical Cord Stem Cell Therapy Clinical Trial for Multiple Sclerosis Gets Green Light

Posted on by

Dallas, TX (PRWEB) April 03, 2014

Translational Biosciences, a subsidiary of Medistem Panama, has received the green light for a phase I/II clinical trial using human umbilical cord-derived mesenchymal stem cells (UC-MSC) for multiple sclerosis from the Comit Nacional de Biotica de la Investigacin (CNEI) Institutional Review Board (IRB) in Panama.

According to the US National Multiple Sclerosis Society, in Multiple Sclerosis (MS), an abnormal immune-mediated T cell response attacks the myelin coating around nerve fibers in the central nervous system, as well as the nerve fibers themselves. This causes nerve impulses to slow or even halt, thus producing symptoms of MS that include fatigue; bladder and bowel problems; vision problems; and difficulty walking. The Cleveland Clinic reports that MS affects more than 350,000 people in the United States and 2.5 million worldwide.

Mesenchymal stem cells harvested from donated human umbilical cords after normal, healthy births possess anti-inflammatory and immune modulatory properties that may relieve MS symptoms. Because these cells are immune privileged, the recipients immune system does not reject them. These properties make UC-MSC interesting candidates for the treatment of multiple sclerosis and other autoimmune disorders.

Each patient will receive seven intravenous injections of UC-MSC over the course of 10 days. They will be assessed at 3 months and 12 months primarily for safety and secondarily for indications of efficacy.

The stem cell technology being utilized in this trial was developed by Neil Riordan, PhD, founder of Medistem Panama. The stem cells will be harvested and processed at Medistem Panamas 8000 sq. ft. ISO-9001 certified laboratory in the prestigious City of Knowledge. They will be administered at the Stem Cell Institute in Panama City, Panama.

From his research laboratory in Dallas, Texas, Dr. Riordan commented, Umbilical cord tissue provides an abundant, non-controversial supply of immune modulating mesenchymal stem cells. Preclinical and clinical research has demonstrated the anti-inflammatory and immune modulating effects of these cells. We look forward to the safety and efficacy data that will be generated by this clinical trial; the first in the western hemisphere testing the effects of umbilical cord mesenchymal stem cells on patients with multiple sclerosis.

The Principle Investigator is Jorge Paz-Rodriguez, MD. Dr. Paz-Rodriguez also serves as the Medical Director at the Stem Cell Institute.

For detailed information about this clinical trial visit http://www.clinicaltrials.gov . If you are a multiple sclerosis patient between the ages of 18 and 55, you may qualify for this trial. Please email trials (at) translationalbiosciences (dot) com for more information about how to apply.

About Translational Biosciences

More here:
Umbilical Cord Stem Cell Therapy Clinical Trial for Multiple Sclerosis Gets Green Light

New York Podiatrist Dr. Jeffrey Adler to Be Interviewed April 5 on NewsTalkRadio 77 WABC About the Use of Stem Cell …

Posted on by

New York, New York (PRWEB) April 03, 2014

Dr. Jeffrey Adler, New York podiatrist and Owner/Medical Director of Adler Footcare New York, will be interviewed by radio personality Laura Smith and taking live calls on New York talk show 77 WABC about the use of stem cells to treat chronic foot pain.

Adler Footcare New York uses live birth stem cells to help treat patients with chronic foot problems such as: Plantar fasciitis, Osteoarthritis, Achilles tendonitis and torn soft tissue. The stem cell treatment is proving to be much more effective than traditional treatments like physical therapy or orthotic therapy.

Stem cells have the ability to replicate themselves or change into the cell type that is needed to repair damaged tissue. The therapy works by directly introducing live stem cells into the affected area causing pain. Its approved by the FDA and consistently reviewed by medical professionals to remove the potential of any communicable diseases.

Dr. Adler often travels to other states to share his knowledge with other doctors in his profession. His latest research on stem cell therapy has gained much interest among his peers in the medical industry.

When compared to traditional treatments, stem therapy is proving to be more successful and longer lasting, Dr. Adler said. We are seeing patients heal much quicker and return to their normal activities much sooner.

To learn more about stem cell replacement therapy or to schedule a consultation with a New York podiatrist at Adler Footcare, call (212) 704-4310 or visit http://www.mynycpodiatrist.com.

About Adler Footcare New York Dr. Jeffrey L. Adler, Medical/Surgical Director and owner of Adler Footcare New York has been practicing podiatric medicine since 1979 and has performed thousands of foot and ankle surgeries. Dr. Adler is board certified in Podiatric Surgery and Primary Podiatric Medicine by the American Board of Multiple Specialties in Podiatry. Dr. Adler is also a Professor of Minimally Invasive Foot Surgery for the Academy of Ambulatory Foot and Ankle Surgeons. As one of only several in the country who perform minimally invasive podiatric surgery, Dr. Adlers patients enjoy significantly reduced recovery times.

Read more from the original source:
New York Podiatrist Dr. Jeffrey Adler to Be Interviewed April 5 on NewsTalkRadio 77 WABC About the Use of Stem Cell ...

Which couples who meet on social networking sites are most likely to marry?

Posted on by

PUBLIC RELEASE DATE:

3-Apr-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, April 3, 2014Nearly 7% of Americans married between 2005-2012 met on social networking sites. How those couples compare to couples who met through other types of online meetings or the "old-fashioned" way in terms of age, race, frequency of Internet use, and other factors is explored in an article in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Cyberpsychology, Behavior, and Social Networking website.

In "First Comes Social Networking, Then Comes Marriage? Characteristics of Americans Married 2005-2012 Who Met Through Social Networking Sites," Jeffrey Hall, PhD, University of Kansas, Lawrence, describes the characteristics that are more common among recently married individuals who met online via social networking sites (SNS).

"Facebook use grew dramatically during the 2005-2012 time period studied," says Brenda K. Wiederhold, PhD, MBA, BCB, BCN, Editor-in-Chief of Cyberpsychology, Behavior, and Social Networking, from the Interactive Media Institute, San Diego, CA. "It will be useful to continue to observe how these trends change as various groups of individuals become more frequent users of SNS," says Dr. Wiederhold.

###

About the Journal

Cyberpsychology, Behavior, and Social Networking is a peer-reviewed journal published monthly online with Open Access options and in print that explores the psychological and social issues surrounding the Internet and interactive technologies, plus cybertherapy and rehabilitation. Complete tables of content and a sample issue may be viewed on the Cyberpsychology, Behavior, and Social Networking website.

About the Publisher

See original here:
Which couples who meet on social networking sites are most likely to marry?

Deadly Dinosaur Chase Reconstructed

Posted on by

A set of prehistoric footprints, said to show meat-eating dinosaurs hunting vegetarian dinos, has just been recreated in a detailed 3-D model.

The frozen-in-time event, dated to at least 112 million years ago, happened at what is now the Paluxy River site in Dinosaur Valley State Park near the town of Glen Rose, Texas just southwest of Fort Worth.

The chase involved 20 to 30-foot-long predatory dinosaurs going after 30 to 50-foot-long dinosaur prey. While paleontologists arent yet certain of the species, Acrocanthosaurus (aka High-spined Lizard) is considered the likely hunter and Pleurocoelus (a hefty and impressively huge plant eater) the hunted.

Could These 10 Animals Be Resurrected?

It looks like one or more big predatory dinosaurs was stalking a herd of about 12 sauropods before the hunters went in for the kill.Some have suggested the tracks show one or more dinosaurs dying, since the footprints of young sauropods (the plant eaters) appear to trail off.

The chase scene has been known for some years. Unfortunately, after American paleontologist Roland Bird originally excavated the preserved footprints in 1940, researchers removed the tracks from their original location, divided them into blocks and transported them to various locations around the world.

Bird had documented the original site with photos and maps, but since that excavation, portions of the tracks have been lost. Peter Falkingham of the Royal Veterinary College, along with colleagues James Farlow and Karl Bates, decided to recreate the full set of dinosaur footprints.

When we first set out to map the Paluxy Rivertrack, creating an accurate 3-D model of the site required use of a large, heavy laser scanner that cost tens of thousands of pounds and was prone to failure especially in the extreme heat in Texas, Falkingham said in a press release.

Chicken from Hell Was a Fowl-Looking Dinosaur

They switched to a process called photogrammetry, which uses multiple digital photographs to generate a 3-D model. The process matches features between images and calculates relative camera positions. The researchers were even able to incorporate some of the original photos taken by Bird.

Read more here:
Deadly Dinosaur Chase Reconstructed

GMO foods have caused nary a sniffle, sneeze or bellyache

Posted on by

From buying organic to gluten-free, consumers seem to be more interested than ever in the ways their food is produced.

This spring, legislators in more than 20 states will consider proposals to mandate special labeling of genetically modified foods, to give shoppers one more bit of information.

Critics say genetically modified foods might be unsafe, but even if they are not, consumers have a right to know what is in what they eat.

So, why not tell people if the ingredients in their cupcakes and cereal have been engineered, and let them decide what to buy?

This may sound reasonable and seem to reflect how our choice-driven marketplace works. But, it reflects a deep misunderstanding about what genetic engineering actually is and how it compares to the changes we have been making to crop plants for thousands of years.

For starters, nearly every food on grocery store shelves has been modified by human hands at the genetic level. In the agriculture world, its called breeding. And, as many of us learned in high school biology class, breeding alters a plants genes so it expresses new traits.

This may be as simple as a new color or flavor, or even resistance to pests and plant diseases.

And, whether we use genetic engineering or more conventional techniques, breeding can mean just tweaking the genes already inside a plant or introducing entirely new ones.

The primary thing that makes genetic engineering unique is the power and precision it gives us to make those changes and then test for safety afterward. It has also given us food that is both safer for our families and better for the environment.

Plants with a built-in resistance to chewing insects, for example, have allowed farmers to use millions of gallons less pesticide every year.

Here is the original post:
GMO foods have caused nary a sniffle, sneeze or bellyache